Omaha, NB 7/2/14; Coralville, TA 7/2/14—Transgenomic has agreed to sell the rights to its SURVEYOR Nuclease technology and the assets to Integrated DNA Technologies (IDT) for a minimum of $4.25 million, including an upfront payment of $3.65 million. Transgenomic will exclusively sublicense rights for SURVEYOR clinical and diagnostic applications from IDT. SURVEYOR Nuclease recognizes and cleaves mismatches arising from SNPs or small insertions and deletions. IDT will sell SURVEYOR Mutation Detection Kits for both gel electrophoresis analysis and use on Transgenomics’s WAVE and WAVE HS systems. SURVEYOR Mutation Detection is also a method for verifying the outcome of gene editing. “The sale of SURVEYOR Nuclease technology to IDT for the noncore research market allows us to focus more of our resources on commercialization efforts in our Patient Testing, Biomarker Identification, and Genetic Assays and Platforms business units, “ stated Transgenomic President and CEO Paul Kinnon. Stephen Gunstream, chief commercial officer at IDT, stated, “These products will be of great benefit to IDT customers, most of whom are in the field of genetic analysis, and of particular use to those whose work involves mutation detection or validation of CRISPR/Cas9 genome editing.”